Thrombosis associated with viral hepatitis

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 4, 2014, Pages 234-239

  Galli, Luca ^a,b   Gerdes, Victor E A ^b   Guasti, Luigina ^a   Squizzato, Alessandro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cytomegalovirus; Epstein Barr virus; Hepatitis; Hepatitis A, B and C virus; Thrombosis

Indexed keywords

EID: 84970976869     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00031     Document Type: Review

References (78)

1. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353: 1167–1173. doi: 10.1016/S0140-6736(98)10266-0.
2. Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587–591. doi: 10.1002/hep.510310307.
3. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006;367:1075–1079. doi: 10.1016/S0140-6736(06) 68474-2.
4. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26–39. doi: 10.1016/S0008-6363(02)00857-X.
5. Squizzato A, Gerdes VEA, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005;93:403–410. doi: http://dx.doi.org/10.1160/TH04-08-0523.
6. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB, Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general over-view and guidelines for a clinical approach. Dig Liver Dis 2007;39:2–17. doi: 10.1016/j.dld.2006.06.008.
7. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147–156. doi: 10.1056/NEJMra1011170.
8. Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, Cerbone AM, et al. The infectious burden in atherothrombosis. Semin Thromb Hemost 2012;38:515– 523.
9. SquizzatoA, GerdesVEA. Viral hepatitis and thrombosis: a narrative review. Semin Thromb Hemost 2012;38:530–534.
10. http://www.cdc.gov, accessed September 2014.
11. Tichelaar VY, Sprenger HG, Makelburg AB, Niesters BG, Kluin-Nelemans HC, Lijfering WM. Active cytomegalovirus infection in patients with acute venous thrombosis: a case-control study. Am J Hematol 2011;86:510–512. doi: 10.1002/ajh.22006.
12. Rahbar A, Soderberg-Naucler C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol 2005; 79:2211–2220. doi: 10.1128/JVI.79.4.2211-2220.2005.
13. Span AH, van Dam-Mieras MC, Mullers W, Endert J, Muller AD, Bruggeman CA. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Eur J Clin Invest 1991;21:331–338. doi: 10.1111/j.1365-2362.1991.tb01378.x.
14. Van Dam-Mieras MC, Muller AD, van Hinsbergh VW, Mullers WJ, Bomans PH, Bruggeman CA. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992;68:364–370.
15. Van Dam-Mieras MC, Bruggeman CA, Muller AD, Debie WH, Zwaal RF. Induction of endothelial cell procoagulant activity by cytomegalovirus infec-tion. Thromb Res 1987;47:69–75. doi: 10.1016/0049-3848(87)90241-6.
16. Sutherland MR, Raynor CM, Leenknegt H, Wright JF, Pryzdial EL. Coagulation initiated on herpesviruses. Proc Natl Acad Sci U S A 1997;94:13510–13514. doi: 10.1073/pnas.94.25.13510.
17. Pryzdial EL, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospho-lipid. Blood 1994;84:3749–3757.
18. Schambeck CM, Hinney K, Gleixner J, Keller F. Venous thromboembolism and associated high plasma factor VIII levels: linked to cytomegalovirus infection? Thromb Haemost 2000;83:510–511.
19. The TH, Kas-Deelen AM, de Maar EF, Driessen C, Harmsen MC, van Son WJ. Cellular and humoral parameters for vascular damage in blood during cytomegalovirus infections. Transplant Proc 2001;33:1813. doi: 10.1016/S0041-1345(00)02692-0.
20. Delbos V, Abgueguen P, Chennebault JM, Fanello S, Pichard E. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect 2007;54:e47–e50. doi: http://dx.doi.org/10.1016/j.jinf.2006.03.031.
21. Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med 2011;22: 195–199. doi: 10.1016/j.ejim.2010.11.006.
22. Squizzato A, Ageno W, Cattaneo A, Brumana N. A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2007;44:e13–e16. doi: 10.1086/509641.
23. Paran Y, Shalev V, Steinvil A, Justo D, Zimmerman O, Finn T, et al. Thrombosis following acute cytomegalovirus infection: a community prospective study. Ann Hematol 2013;92:969–974. doi: 10.1007/s00277-013-1715-3.
24. Madalosso C, de Souza NF, Jr IDM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998;66:294–297. doi: 10.1097/00007890-199808150-00003.
25. Protopapa MN, Velissaris D, Mougiou A, Siagkris D. Cytomegalovirus-associated splenic infarcts in an adult immune-competent man: a case report and review of the literature. J Med Case Rep 2014;8:85. doi: 10.1186/1752-1947-8-85.
26. Mashav N, Saar N, Chundadze T, Steinvil A, Justo D. Epstein-Barr virus-associated venous thromboembolism: a case report and review of the literature. Thromb Res 2008;122:570–571. doi: 10.1016/j.thromres.2008.03.005.
27. Yamazaki M, Asakura H, Kawamura Y, Ohka T, Endo M, Matsuda T. Transient lupus anticoagulant induced by Epstein-Barr virus infection. Blood Coagul Fibrinolysis 1991;2:771–774. doi: 10.1097/00001721-199112000-00012.
28. Dalpke AH, Thomssen R, Ritter K. Oxidative injury to endothelial cells due to Epstein-Barr virus-induced autoantibodies against manganese superoxide dismutase. J Med Virol 2003;71:408–416. doi: 10.1002/jmv.10501.
29. Zis P, Kontogeorgi E, Karakalos D, Pavlopoulou D, Sevastianos VA. Cerebral venous thrombosis as an extrahepatic manifestation of acute anicteric hepatitis A infection. Case Rep Neurol Med. 2012;2012:120423. doi: 10.1155/2012/120423.
30. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008; 103:1283–1297, quiz 1298. doi: 10.1111/j.1572-0241.2008.01825.x.
31. Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014;31:891–903. doi: 10.1007/s12325-014-0138-4.
32. Shoenfeld Y. Systemic antiphospholipidsyndrome. Lupus 2003;12:497–498. doi: 10.1191/0961203303lu396xx.
33. Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al . Anti cardi ol i pi n anti bodi es i n pati ents wi th l i ver di sease. Am J Gastroenterol 1999; 94: 2983–2987. doi: 10.1111/j.1572-0241.1999.01447.x.
34. Biron C, Andreani H, Blanc P. Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury. J Lab Clin Med 1998;131:243–250. doi: 10.1016/S0022-2143(98)90096-8.
35. Violi F, Ferro D, Basili S, Artini M, Valesini G, Levrero M, et al. Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. J Investig Med 1995;43:550–554.
36. Prieto J, Yuste JR, Beloqui O, Civeira MP, Riezu JI, Aguirre B, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996;23: 199–204. doi: 10.1002/hep.510230201.
37. Daniels AH, Wilson CL, Harrison RA. Hepatitis C-associated leukocytoclas-ticvasculitis with anticardiolipin antibodies causing penile necrosis and deep venous thrombosis in the absence of cryoglobulinemia. J Hosp Med 2008;3: 170–172. doi: 10.1002/jhm.261.
38. Tripodi A, Primignani M, Chantarangkul V, Dell’Era A, Clerici M, de Franchis R, et al. An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009;137:2105–2111. doi: 10.1053/j.gastro.2009.08.045.
39. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010;52: 249–255. doi: 10.1002/hep.23653.
40. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013;59:265–270. doi: 10.1016/j.jhep.2013.03.036.
41. Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocyto-penia among patients with chronic hepatitis C: a systematic review. J Viral Hepat 2011;18:1–7. doi: 10.1111/j.1365-2893.2010.01366.x.
42. Streiff MB, Mehta S, Thomas DL. Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002;35:947–952. doi: 10.1053/jhep.2002.32486.
43. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006;23:1055– 1065. doi: 10.1111/j.1365-2036.2006.02889.x.
44. Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014–1020. doi: 10.1136/gut.2004.057893.
45. Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014;146:442–452. doi: 10.1053/j.gastro.2013.10.012.
46. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocyto-penia. ELEVATE Study Group. N Engl J Med 2012;367:716–724.
47. Provan D, Saleh M, Goodison S, Rafi R, Stone N, Hamilton JM, et al. The safety profile of eltrombopag, a novel, oral platelet growth factor, in thrombocyto-penic patients and healthy subjects. J. Clin Oncol 2006;24:18596.
48. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004;104:Abstract 3888.
49. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AØ, Nørgaard M, Zhao S, et al. Risk of venous thromboembolism in patient with primary chronic immune thrombocytopenia: a Danish population-base cohort study. Br J Haematol 2011;152:360–362. doi: 10.1111/j.1365-2141.2010.08418.x.
50. Haselboeck J, Pabinger I, AY C, Koder S, Panzer S. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol 2012;91:109–113. doi: 10.1007/s00277-011-1249-5.
51. Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010;47:289–298. doi: 10.1053/j.seminhematol.2010.03.002.
52. Lambert MP. Platelets and eltrombopag: a not-so-sticky situation. Blood 2012;119:3876–3877. doi: 10.1182/blood-2012-03-410415.
53. Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associatedwith chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000;7:466–470. doi: 10.1046/j.1365-2893.2000.00245.x.
54. Ortega-Ibarra FS, Remes-Troche JM. Retinal thrombosis secondary to the combination therapy of pegylated interferon and ribavirin for chronic hepatitis C virus infection. A rare complication. Rev Esp Enferm Dig. 2013 May-Jun;105:291–292. doi: 10.4321/S1130-01082013000500007.
55. Nicolò M, Artioli S, La Mattina GC, Ghiglione D, Calabria G. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005;15:811–814.
56. Sene D, Touitou V, Bodaghi B, Saadoun D, Perlemuter G, Cassoux N, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007;13:3137–3140. doi: 10.3748/wjg.v13.i22.3137.
57. Murata M, Tamura Y, Ohsawa M, Hirano T, Matsuo T, Murata T. Central retinal vein occlusion in hypertensive patients with chronic hepatitis C treated with interferon alpha and ribavirin. Jpn J Ophthalmol 2008;52:511–513. doi: 10.1007/s10384-008-0585-z. Epub 2008 Dec 17.
58. Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009;53:598–602. doi: 10.1007/s10384-009-0738-8.
59. Balderramo DC, García O, Colmenero J, Espinosa G, Forns X, Ginès P. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Dig Liver Dis 2009;41:e4–e7. doi: 10.1016/j.dld. 2007.11.029.
60. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998;93:2441–2444. doi: 10.1111/j.1572-0241.1998.00701.x.
61. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283–291. doi: 10.1016/S0168-8278(96)80113-9.
62. Horigome H, Takezono Y, Fujino N, Uchida A, Murasaki G. [A case of ischemic colitis associated with interferon treatment]. Nihon Shokakibyo Gakkai Zasshi 1996;93:181–184.
63. Wenner WJ, Piccoli DA. Colitis associated with alpha interferon? J Clin Gastroenterol 1997;25:398–399.
64. Punnam SR, Pothula VR, Gourineni N, Punnam A, Ranganathan V. Interferon-ribavirin-associated ischemic colitis. J Clin Gastroenterol 2008;42:323–325. doi: 10.1097/01.mcg.0000225637.37533.68.
65. Tada H, Saitoh S, Nakagawa Y, Hirana H, Morimoto M, Shima T, et al. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J Gastroenterol 1996;31:582–584. doi: 10.1007/BF02355061.
66. Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol 2006;20:661–663.
67. Kawaguchi T, Ide T, Itou M, Suetsugu M, Yoshioka S, Sakata M, et al. Ischaemic colitis during interferon treatment for chronichepatitis C: report of two cases and literature review. J Viral Hepat. 2012,19:e220–e224. doi: 10.1111/j.1365-2893.2011.01501.x.
68. Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS. Ischemic colitisduring interferon-ribavirin therapy for chronic hepatitis C: A case report. World J Gastroenterol 2012;18:4233–4236. doi: 10.3748/wjg.v18.i31.4233.
69. Chang L, Kahler KH, Sarawate C, Quimbo R, Kralstein J. Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol Motil 2008;20:36–42. doi: 10.1111/j.1365-2982.2007.01015.x.
70. Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011;35:526–533. doi: 10.1016/j.clinre.2011.03.011.
71. Wright M, Goldin R, Hellier S, Knapp S, Frodsham A, Hennig B, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206–1210. doi: 10.1136/gut.52.8.1206.
72. Levy GA, Liu M, Ding J, Yuwaraj S, Leibowitz J, Marsden PA, et al. Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol 2000;156:1217–1225. doi: 10.1016/S0002-9440(10)64992-9.
73. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The Fgl2/ fibroleukinprothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003;112:58– 66. doi: 10.1172/JCI18114.
74. Poujol-Robert A, Boëlle PY, Conti F, Durand F, Duvoux C, Wendum D, et al. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clin Res Hepatol Gastroenterol 2014;38:570–576. doi: 10.1016/j.clinre.2014.07.004.
75. Lertpipopmetha K, Auewarakul CU. High incidence of hepatitis B infection-associated cirrhosis and hepatocellular carcinoma in the Southeast Asian patients with portal vein thrombosis. BMC Gastroenterol. 2011;11:66. doi: 10.1186/1471-230X-11-66.
76. Chen H, Trilok G, Wang F, Qi X, Xiao J, Yang C. A single hospital study on portal vein thrombosis in cirrhotic patients-clinical characteristics & risk factors. Indian J Med Res 2014;139:260–266. doi: 10.1111/j.1538-7836.2011.04429.x.
77. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011;9:1713– 1723. doi: 10.1111/j.1538-7836.2011.04429.x.
78. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49:1017–1044. doi: 10.1002/hep.22742.